New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced the ...
With the rapid introduction of novel breast cancer therapies, recognizing and managing side effects is essential to maintain adherence and improve outcomes. As novel oral endocrine therapies and ...
About The Study: This comparative effectiveness study found that initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in ...
Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium Avenzo Therapeutics, Inc. ( ...
The weighted incidence rate of autoimmune rheumatic diseases was 51.90 and 58.41 per 100,000 person-years in adults with type 2 diabetes initiating SGLT-2 inhibitors and sulfonylureas, respectively.
If you click on links we provide, we may receive compensation. They wore equally classic, but very different, lightweight layers Nicol Natale is a shopping writer at PEOPLE with an eye for celebrity ...
Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results